Full history for every metric is available with a Kvantra account
Stock profile
Orexigen Therapeutics, Inc. (OREX)
Current price
0.22 USD-34.42%
Last close 3 Apr 2018Benchmarks
Key financial summary
Financials in USD| 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 4 | 3 | 3 | 56 | 24 | 34 | 75 |
| Operating profit | $m | -57 | -206 | |||||
| Net profit | $m | -28 | -90 | -78 | -38 | -69 | -25 | -25 |
| EPS reported | $ | -1.62 | -1.62 | |||||
| Operating cashflow per share | $ | - | -7.24 | |||||
| Capex per share | $ | - | 0.02 | |||||
| FCF per share | $ | - | -7.26 | |||||
| Free cash flow | $m | -110 | -137 | |||||
| Net debt | $m | -25 | -45 | |||||
| Book value equity | $m | 57 | -62 | |||||
| Book value per share | $ | 3.76 | -4.11 | |||||
| Number of shares | m | 15.16 | 15.16 | |||||
| DPS (TTM paid) | $ | - | 0.00 |
Financial summary
Financials in USD| 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | 0.46 | 0.06 | |||||
| P/S LTM | x | 0.78 | 0.00 | |||||
| P/FCF LTM | x | -0.24 | 0.00 | |||||
| EV/EBITDA LTM | x | -1.05 | 1.05 | |||||
| EV/Sales LTM | x | - | -0.39 | |||||
| Earnings Yield LTM | % | - | -725.55% | |||||
| FCF Yield | % | -417.06% | - | |||||
| Quality | ||||||||
| ROE | % | - | -54.24% | |||||
| ROIC | % | - | -22.41% | |||||
| Operating margin | % | - | -169.01% | |||||
| Gross margin | % | - | 76.28% | |||||
| FCF/Sales | % | - | -326.45% | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | +37.82% | +204.09% | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | - | 0.00% | |||||
| Dividend Growth | % | - | - | |||||
| Payout Ratio | % | - | -81.34% | |||||
| FCF/Debt | x | -1.39 | -5.39 | |||||
| Net Debt/EBITDA | x | - | 1.05 | |||||
| EBIT/Net interest | x | - | -7.26 | |||||
| Net debt/market cap | % | -93.67% | - | |||||
| Net debt/Equity | x | -0.43 | 0.72 | |||||
| Gross debt/equity | x | 1.39 | -0.41 | |||||
Company overview
No description available.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
OR
Orexigen Therapeutics, Inc. (OREX)
OREX · NASDAQ · Healthcare
0.22 USD-34.42%
Benchmarks
Financialsin USD
20152016TTM
Total revenue $m243475
Operating profit $m-57-206
Net profit $m-69-25-25
EPS reported $-1.62-1.62
About
No description available.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free